Sign In  |  Register  |  About Walnut Creek Guide  |  Contact Us

Walnut Creek, CA
September 01, 2020 1:43pm
7-Day Forecast | Traffic

  • Search Hotels in Walnut Creek Guide

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bluebird Bio (NQ: BLUE )

0.4057 +0.0236 (+6.18%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bluebird Bio

< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
21 22 Next >
With FDA Submission For Sickle Cell Gene Therapy, Bluebird Bio Can Potentially Have 3 Approved Products By 2023
Via Benzinga
bluebird bio Submits Biologics License Application (BLA) to FDA for lovotibeglogene autotemcel (lovo-cel) for Patients with Sickle Cell Disease (SCD) 12 years and Older with a History of Vaso-Occlusive Events
From bluebird bio, Inc.
Via Business Wire
Cancer And Diabetes Remain Among The Deadliest And Most Debilitating Diseases — Is Gene Therapy The Solution? One Company, Genprex, Inc. (NASDAQ: GNPX), Thinks So
On their own, cancer or diabetes can be debilitating and deadly. The two are common diseases with tremendous impact on health worldwide. 
Via Benzinga
bluebird bio Inc. (NASDAQ: BLUE) Leading the Way in Thursday Trading Based on Percentage Gain
Via Investor Brand Network
Should Investors Buy the Dip With Bluebird Bio Stock?
The case for buying the dip isn't exactly a slam dunk. 
Via The Motley Fool
1 Small-Cap Stock That Could Soar in 2023
Investors should think twice before initiating a position. 
Via The Motley Fool
Why Bluebird Bio Stock Is Sinking This Week
A potential regulatory delay is weighing on the biotech's stock this week. 
Via The Motley Fool
Why ViewRay Shares Are Trading Lower By 32%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers CXApp Inc. (NASDAQ: CXAI) jumped 105% to $3.28 after climbing over 20% on Wednesday. 
Via Benzinga
$2M Price Tag for Sickle Cell Gene Therapies Could Be Cost-Effective Under Certain Scenarios, Finds ICER Analysis
Via Benzinga
Nasdaq Surges 100 Points; US Producer Prices Drop In March
U.S. stocks traded mostly higher this morning, with the Nasdaq Composite gaining around 100 points on Thursday. Following the market opening Thursday, the Dow traded up 0.01% to 33,650.06 while the... 
Via Benzinga
Analyst Ratings for bluebird bio
Via Benzinga
bluebird bio Earnings Perspective: Return On Capital Employed
Via Benzinga
Why Bluebird Bio Shares Are Plunging Today
Via Benzinga
Top 5 Health Care Stocks Which Could Rescue Your Portfolio This Month
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. 
Via Benzinga
What's the Better Dip to Buy: CRISPR Therapeutics vs. Bluebird Bio
Both biotechs are aiming for the same markets, but they are not equally risky. 
Via The Motley Fool
Better Gene-Editing Stock: Editas Medicine vs. Bluebird Bio
Neither stock is a good choice for those who can't handle a lot of risk. 
Via The Motley Fool
S&P 500 Up 1%; Bluebird Bio Shares Plummet
U.S. stocks traded higher toward the end of trading, with the S&P 500 gaining over 1% on Wednesday. The Dow traded up 0.74% to 32,632.35 while the NASDAQ rose 1.51% to 11,893.07. The S&P 500, also... 
Via Benzinga
Stocks Rise As Investors Bet On Bank Recovery
Stocks are swinging higher today, as bond yields retreat and Wall Street bets that the worst of the regional banking crisis is in the rearview mirror. 
Via Talk Markets
bluebird bio Earnings Preview
Via Benzinga
Analyst Expectations for bluebird bio's Future
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Why Kodiak Sciences Shares Are Trading Higher By 18%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers LogicMark, Inc. (NASDAQ: LGMK) shares jumped 76.1% to $0.2466 after the company announced financial results for the year ended 2022. The company reported FY22 revenue of $11.9 million. 
Via Benzinga
Nasdaq Rises 1%; US Pending Home Sales Increase In February
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining over 100 points on Wednesday. The Dow traded up 0.58% to 32,580.89 while the NASDAQ rose 1.09% to 11,843.85. The S&P... 
Via Benzinga
UniFirst, Progress Software, SomaLogic And Other Big Stocks Moving Lower On Wednesday
U.S. stocks traded higher, with the Dow Jones gaining around 200 points on Wednesday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
US Stocks Open Higher, Dow Jumps Over 200 Points
U.S. stocks traded higher this morning, with the Dow Jones gaining over 200 points on Wednesday. Following the market opening Wednesday, the Dow traded up 0.72% to 32,628.42 while the NASDAQ rose 1.33%... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
bluebird bio Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Operational Progress
From bluebird bio, Inc.
Via Business Wire
Coya Therapeutics Enters First-Of-Its-Kind Partnership With Multi-Billion Dollar Drug Company — Why This Is A Major Moment For Drug Development
Houston-based Coya Therapeutics (NASDAQ: COYA) has entered into a partnership with Dr. Reddy’s Laboratories Ltd. (NYSE: RDY), a world-leading pharmaceutical company based in India. 
Via Benzinga
Hefty Listing Price Of New Drugs For Cancer, Rare Diseases Put Pressure On Annual Hike For Older Drugs
New branded medicines are coming to market with ever-higher price tags as soon as the first day. Amgen Inc's (NASDAQ: AMGN) lung cancer treatment, Lumakras, carried a hefty price tag of $17,900 per... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 7, 2023
Via Benzinga
< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
21 22 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 WalnutCreekGuide.com & California Media Partners, LLC. All rights reserved.